Flow Diversion Aneurysm Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (FDS, Intrasaccular flow disruption devices), By End User (Hospitals, Specialty clinics), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.02 Billion
CAGR (2026-2031)	7.86%
Fastest Growing Segment	FDS
Largest Market	North America
Market Size (2031)	USD 3.18 Billion

Market Overview

The Global Flow Diversion Aneurysm Treatment Market will grow from USD 2.02 Billion in 2025 to USD 3.18 Billion by 2031 at a 7.86% CAGR. Flow diversion aneurysm treatment utilizes a dense mesh stent placed across the neck of an aneurysm to redirect blood flow along the parent vessel, thereby inducing thrombosis within the sac and reconstructing the arterial wall. The primary drivers supporting market growth include the rising global geriatric population and a marked clinical preference for minimally invasive endovascular techniques over traditional surgical clipping. According to the Brain Aneurysm Foundation, in 2024, an estimated 6.7 million people in the United States alone had an unruptured brain aneurysm, highlighting the substantial addressable patient population necessitating durable preventive solutions.

Despite the favorable adoption rates, the market faces a significant challenge regarding the high cost of these implantable devices and the complex reimbursement landscape in developing healthcare systems. These economic barriers can limit patient access and delay the approval of new technologies in price-sensitive regions, potentially hindering the broader global expansion of flow diversion therapies.

Key Market Drivers

Technological innovations in flow diverter device design are currently acting as a primary catalyst for market expansion, particularly through the development of surface-modified implants that enhance endothelialization and reduce thrombogenicity. Manufacturers are introducing advanced mesh constructs that improve hemodynamic diversion efficacy while minimizing the requirement for prolonged dual antiplatelet therapy, thereby expanding the treatable patient population to include those at higher bleeding risk. For instance, according to Phenox GmbH, December 2025, in the 'COATING' randomized controlled trial results, the p64-MW-HPC surface-modified flow diverter demonstrated a favorable safety profile with no statistically significant difference in thromboembolic events compared to standard devices, validating the clinical viability of these next-generation implants. These engineering breakthroughs are directly addressing clinical hesitations regarding device-related thrombosis, encouraging broader adoption of endovascular solutions for complex intracranial aneurysms.

The rising global prevalence of cerebrovascular disorders is concurrently necessitating the widespread utilization of these preventive interventional therapies. The escalating burden of stroke and unruptured aneurysms is compelling healthcare systems to prioritize minimally invasive flow diversion to mitigate the catastrophic economic and clinical consequences of rupture. According to the American Heart Association, January 2025, in the '2025 Heart Disease and Stroke Statistics Update', stroke deaths in the United States increased by 28.7% between 2012 and 2022, underscoring the urgent need for effective preventive treatments. This surging demand for neurovascular interventions is reflected in the robust financial performance of key market players. According to Stryker, October 2025, the company's MedSurg and Neurotechnology segment reported a 14.4% increase in net sales for the third quarter of 2025, highlighting the accelerated commercial uptake of advanced neuro-interventional technologies.

Download Free Sample Report

Key Market Challenges

The high acquisition cost of flow diversion devices combined with a complex reimbursement landscape creates a substantial economic barrier that impedes market penetration. Hospitals and procurement departments often face strict budget caps, and the premium pricing of these dense mesh stents can exceed the bundled payments provided by public and private insurers. When reimbursement rates lag behind the price of new medical technologies, healthcare facilities are forced to absorb the financial deficit, leading to restricted inventory and stringent approval processes for device usage. This financial misalignment effectively limits patient access to flow diversion therapy, particularly in developing healthcare systems where funding is prioritized for lower-cost, traditional treatments.

According to the Society of NeuroInterventional Surgery, in 2024, the average implant cost alone for treating an unruptured aneurysm with a flow diverter was approximately $12,400. This significant fixed cost for a single disposable unit creates a difficult adoption curve for institutions operating under fixed capitation payments. Consequently, despite the clinical advantages, the financial strain prohibits the widespread scalability of the procedure, confining the market growth to affluent regions or well-funded specialized centers.

Key Market Trends

The integration of AI-driven simulation software for pre-procedural sizing is fundamentally altering the planning phase of neurovascular interventions by minimizing device sizing errors and reducing material wastage. Clinicians are increasingly leveraging these advanced computational models to predict vessel wall apposition and hemodynamic changes before implantation, ensuring optimal stent selection for complex geometries. This shift is critical in mitigating the financial risks associated with the high cost of flow diverters, as accurate sizing reduces the likelihood of device malposition or the need for additional corrective implants. According to Interventional Neuroradiology, March 2025, in the 'Virtual simulation for flow-diverter selection and sizing in the endovascular treatment of intracranial aneurysms: A systematic review and meta-analysis', the use of virtual simulation software achieved a high device deployment success rate of 96% while maintaining a low complication rate of 4%, validating the technology's role in enhancing procedural precision.

Concurrently, the development of low-profile devices for distal and tortuous vasculature access is expanding the addressable patient population to include those with aneurysms in previously inaccessible anatomical locations. Manufacturers are engineering next-generation delivery systems compatible with smaller microcatheters, such as 0.021-inch platforms, allowing interventionalists to navigate sharp turns in the Circle of Willis that were challenging for bulkier first-generation constructs. This innovation enables the treatment of distal aneurysms without compromising the radial force required for effective flow diversion. According to the Journal of NeuroInterventional Surgery, November 2025, in the study 'FRED X flow diversion stenting for unruptured intracranial aneurysms', the next-generation low-profile device demonstrated a 74.8% adequate occlusion rate at follow-up, confirming the clinical viability and efficacy of these refined delivery platforms in managing complex neurovascular pathologies.

Segmental Insights

The Flow Diversion Stent (FDS) segment currently represents the fastest-growing category within the Global Flow Diversion Aneurysm Treatment Market. This rapid expansion is primarily driven by the device's distinct ability to effectively manage complex, wide-necked intracranial aneurysms that are often unsuitable for conventional endovascular coiling. FDS devices function by reconstructing the parent artery and redirecting hemodynamic pressure, which facilitates natural vessel healing and long-term occlusion. Furthermore, continued clearances from the U.S. Food and Drug Administration (FDA) for expanded clinical indications have significantly broadened patient eligibility, establishing FDS as a preferred minimally invasive option for neurovascular specialists.

Regional Insights

North America maintains a dominant position in the Global Flow Diversion Aneurysm Treatment Market, driven primarily by a high prevalence of intracranial aneurysms and a well-established healthcare infrastructure. The region benefits significantly from the strong presence of key medical device manufacturers and favorable reimbursement policies that facilitate patient access to treatment. Furthermore, the U.S. Food and Drug Administration (FDA) plays a critical role by granting timely approvals for new flow diversion devices, which accelerates clinical adoption. These factors collectively support the sustained leadership of North America in this sector.

Recent Developments

• In December 2025, Phenox released interim safety results from the COATING randomized controlled trial, which evaluated the p64 MW HPC Flow Diverter. The study was significant for being the first to compare a surface-modified flow diverter managed with single antiplatelet therapy against a bare device using standard dual antiplatelet therapy. The presented data focused on safety outcomes up to one month post-procedure, analyzing the potential of the Hydrophilic Polymer Coating to reduce thrombogenicity. These findings were intended to support the use of the device in patients who might benefit from a reduced antiplatelet regimen, addressing a key clinical need in aneurysm treatment.
• In July 2025, Stryker announced the commercial launch of the Surpass Elite Flow Diverter across the United States, South Korea, and Europe. This next-generation device was introduced with the proprietary BioStealth Surface technology, a surface modification designed to enhance thromboresistance and reduce thrombin generation. The system also featured a reengineered implant design with a higher braid angle and optimized heat treatment, aiming to improve vessel-wall apposition and opening reliability. The company implemented a phased introduction strategy focused on physician education and real-world clinical validation to ensure procedural success and streamline deployment in complex neurovascular interventions.
• In November 2024, MicroPort NeuroTech announced the completion of the first post-market implantation of the Tubridge Plus Flow Diverter in China. The procedure was successfully performed at Changhai Hospital to treat an aneurysm in the ophthalmic segment of the internal carotid artery. This upgraded device is distinguished by its full-body radiopacity, achieved through radiopaque wires that improve visualization during the intervention. The Tubridge Plus also offers enhanced radial support and is designed for deployment via a lower-profile microcatheter, features that aim to facilitate precise positioning and better conformity to the vessel wall during complex aneurysm repairs.
• In January 2024, new clinical data was reported regarding the safety and efficacy of the Pipeline Vantage Flow Diverter with Shield Technology for the treatment of unruptured intracranial aneurysms. The findings were part of the multicenter PEDVU study conducted across several hospitals in the United Kingdom. The research demonstrated that this fourth-generation device achieved acceptable safety outcomes and effective aneurysm occlusion rates. The study highlighted that earlier technical challenges associated with the device's delivery had been effectively addressed in the updated iteration, providing physicians with a reliable option for flow diversion therapy in standard clinical practice.

Key Market Players

• Acandis GmbH
• BALT Group
• Cardinal Health Inc
• Endologix LLC
• Evasc Medical Systems Corp
• Imperative Care Inc
• InspireMD Inc
• Johnson and Johnson
• Lepu Medical Technology Beijing Co. Ltd
• Medtronic Plc

By Product	By End User	By Region
FDS Intrasaccular flow disruption devices	Hospitals Specialty clinics	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Flow Diversion Aneurysm Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Flow Diversion Aneurysm Treatment Market, By Product:

• FDS
• Intrasaccular flow disruption devices

• Flow Diversion Aneurysm Treatment Market, By End User:

• Hospitals
• Specialty clinics

• Flow Diversion Aneurysm Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE